A Phase I Study of VS-5584 in Patients with Lymphoma or Advanced Solid Tumors

Full Title

A Phase I, Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects with Advanced Non-Hematologic Malignancies or Lymphoma


The purpose of this study is to determine the highest dose of VS-5584 that can be given safely in patients with advanced solid tumors or lymphomas that are not responding to standard therapies or for which no standard therapies exist. VS-5584 blocks two proteins that cancer cells need to grow: PI3 kinase (PI3K) and mTOR. VS-5584 is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an advanced solid cancer or lymphoma which is no longer responding to standard therapies or for which no standard therapy exists.
  • Patients must have recovered from the serious side effects of previous treatments before entering the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Anna Varghese at 646-888-4308.